Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
480.7 USD +0.35% Intraday chart for Vertex Pharmaceuticals Incorporated -0.48% +18.15%
Sales 2024 * 10.75B 14.77B Sales 2025 * 11.67B 16.03B Capitalization 124B 170B
Net income 2024 * 3.96B 5.44B Net income 2025 * 4.46B 6.13B EV / Sales 2024 * 10.2 x
Net cash position 2024 * 13.97B 19.19B Net cash position 2025 * 18.59B 25.54B EV / Sales 2025 * 9.04 x
P/E ratio 2024 *
32 x
P/E ratio 2025 *
28.3 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424 MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
More news
1 day+0.35%
1 week-0.48%
Current month+5.58%
1 month+12.17%
3 months+17.60%
6 months+18.23%
Current year+18.15%
More quotes
1 week
472.61
Extreme 472.61
485.40
1 month
432.22
Extreme 432.22
486.43
Current year
391.01
Extreme 391.01
486.43
1 year
335.82
Extreme 335.82
486.43
3 years
176.36
Extreme 176.36
486.43
5 years
165.23
Extreme 165.23
486.43
10 years
63.68
Extreme 63.68
486.43
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 17-01-31
Chairman 68 09-07-07
Director of Finance/CFO 56 19-04-09
Members of the board TitleAgeSince
Director/Board Member 68 17-06-07
Chairman 68 09-07-07
Director/Board Member 64 97-12-31
More insiders
Date Price Change Volume
24-06-14 480.7 +0.35% 641,768
24-06-13 479 +0.68% 808,498
24-06-12 475.8 -1.19% 1,245,007
24-06-11 481.5 -0.36% 882,034
24-06-10 483.3 +0.05% 1,253,805

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7 USD
Average target price
463.4 USD
Spread / Average Target
-3.60%
Consensus